Patents Examined by Brian Gangle
  • IL-15 and IL-15R\alpha sushi domain based immunocytokines
    Patent number: 11753454
    Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15R?) or derivatives thereof; and uses thereof.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: September 12, 2023
    Assignees: Cytune Pharma, INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: Sebastien Daniel Morisseau, Geraldine Teppaz, Yannick Laurent Joseph Jacques, Bruno Gilbert Marc Robert, Guy Luc Michel De Martynoff, David Bechard
  • Inhibitor of RNA polymerase II
    Patent number: 11752192
    Abstract: An inhibitor of RNA polymerase II is described, wherein said inhibitor is selected a moiety which targets a protein selected from cyclin kinase 12 (CDK12) or its recruiting protein PAF1C. Particular examples of such inhibitors are polypeptides expressed by a gene selected from IldD, IldR, nlpD or rfaH of a bacterial species, such as a commensal bacteria or asymptomatic carrier, or a variant of said protein. Inhibitors may be based upon bacterial Sigma S or NplD proteins. These inhibitors are useful in therapies, to suppress protein expression. Thus they may be used as immunosuppressants, anti-inflammatory or anti-infection agents.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: September 12, 2023
    Inventors: Catharina Svanborg, Nina Filenko, Ines Ambite
  • Primate retinal pigment epithelium cell-specific promoter
    Patent number: 11739349
    Abstract: The present invention to a method for expressing an exogenous gene specifically in cells of the retinal pigment epithelium of a primate, this method comprising the step of delivering an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or consisting of a nucleic acid sequence of at least 400 bp having at least 80% overall identity to the sequence of SEQ ID NO:1, to cells of the retinal pigment epithelium of the primate, wherein this isolated nucleic acid molecule specifically leads to the expression of an exogenous gene in cells of the retinal pigment epithelium of primates when a nucleic acid sequence coding for the exogenous gene is operatively linked to this isolated nucleic acid molecule.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: August 29, 2023
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: Josephine Juettner, Jacek Krol, Botond Roska
  • Cell-based assay using electrophysiological activity measured with microelectrode arrays
    Patent number: 11740230
    Abstract: Methods for detecting and/or quantifying the potency of an agent using a cell-based assay are disclosed. A mammalian cell culture is grown upon a microelectrode array (MEA) which is used to measure an electrophysiological response of the mammalian cell culture. The cell culture is exposed to the agent, generally in at least two different dosages. The potency of the agent is detected by measuring a change in the electrophysiological responses associated with the at least two dosages when compared to a control condition. These changes can include the weighted mean firing rate (wMFR) and bursting of the cells.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: August 29, 2023
    Assignee: Batelle Memorial Institute
    Inventor: Nicholas J. Machesky
  • Polysaccharide and uses thereof
    Patent number: 11738076
    Abstract: Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: August 29, 2023
    Inventors: Michael T. Kowarik, Michael L. Wetter, Stefan J. Kemmler, Micha A. Häuptle, Veronica Gambillara, Manuela Mally
  • Immunogenic compositions comprising
    Patent number: 11738077
    Abstract: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: August 29, 2023
    Inventors: Jeremy Kroll, Mike Roof
  • Anti-IL-36R antibody formulations
    Patent number: 11730812
    Abstract: The present invention relates to anti-interleukin-36 receptor (anti-IL-36R1) antibody formulations for administration to a subject.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: August 22, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sandra Nicole Denkinger, Anna Maria Steiner, Derrick Spencer Katayama, Rajni Prasad Mehra, Ingo Michael Presser, Ravija Singh, Sara Kay Wright
  • Bacterial biofilms and cancer
    Patent number: 11730774
    Abstract: Compositions for the treatment of colorectal cancer target bacterial biofilms in the gastrointestinal tract. Methods of treatment include one or more agents which target bacteria and the bacterial biofilms.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 22, 2023
    Assignee: The Johns Hopkins University
    Inventors: Cynthia L. Sears, Christine Craig, Drew M. Pardoll
  • Mutant NGAL proteins and uses thereof
    Patent number: 11730790
    Abstract: In one aspect the present invention is directed to mutant Neutrophil gelatinase-associated lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: August 22, 2023
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jonathan Barasch, Andong Qiu
  • Composition for the treatment of antibody deficiencies
    Patent number: 11718661
    Abstract: The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore, SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels, these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: August 8, 2023
    Assignees: INSERM (Instut National de la Santé et de la Recherche Médicale), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP)
    Inventors: Guy Gorochov, Martin Larsen, Delphine Sterlin, Jehane Fadlallah
  • Vaccines targeting
    Patent number: 11718648
    Abstract: Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 8, 2023
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • CRP capture/detection of gram positive bacteria
    Patent number: 11718651
    Abstract: Described herein are engineered microbe-targeting molecules, microbe-targeting articles, kits comprising the same, and uses thereof. Such microbe-targeting molecules, microbe-targeting articles, or the kits comprising the same can bind or capture of a microbe or microbial matter thereof, and can thus be used in various applications, such as diagnosis or treatment of an infection caused by microbes in a subject or any environmental surface.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: August 8, 2023
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Alexander L. Watters, Donald E. Ingber, Mark J. Cartwright, Michael Super, Martin Rottman, Evangelia Murray, Brendon Dusel
  • Nucleic acid-based botulinum neurotoxin for therapeutic use
    Patent number: 11707510
    Abstract: The invention relates to a botulinum neurotoxin-encoding nucleic acid for therapeutic use. The invention further relates to the transfection of skeletal muscle cells and smooth muscle cells and the glands of the skin, and of other skin cells with botulinum neurotoxin (BoNT)-encoding nucleic acids (RNA or DNA) with or without the use of a secretory signal, for therapeutic and/or cosmetic purposes.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: July 25, 2023
    Assignee: PRECLINICS DISCOVERY GMBH
    Inventor: Jonas Füner
  • Compositions and methods for treating cholestatic disease
    Patent number: 11701394
    Abstract: The invention provides compositions and methods for use in the treatment and prevention of cholestatic diseases.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: July 18, 2023
    Assignee: Seres Therapeutics, Inc.
    Inventors: Madhumitha Nandakumar, Alice Peiyu Liou, Elizabeth Moritz Halvorsen, Gregory McKenzie, Edward J. O'Brien, David Cook
  • -based endospore display platform, products and methods
    Patent number: 11702665
    Abstract: Signal sequences useful for targeting proteins and peptides to the surface of endospores produced by Paenibacillus family members and methods of using the same are provided. The display of heterologous molecules, such as peptides, polypeptides and other recombinant constructs, on the spore surface of Paenibacillus family members, using particular N-terminal targeting sequences and derivatives of the same, are also provided.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: July 18, 2023
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Damian Curtis, Benjamin L. Golomb, Dilara Ally, Florencia A. Ficarra, Rauf Salamzade, Bjorn A. Traag
  • Multivalent pneumococcal vaccines
    Patent number: 11701416
    Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: July 18, 2023
    Assignee: Affinivax, Inc.
    Inventors: Richard Malley, Yingjie Lu, Fan Zhang, Teresa J. Broering, Shite Sebastian, Velupillai Puvanesarajah, George R. Siber
  • Anti-PD-L1 antibody for detecting PD-L1
    Patent number: 11697686
    Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDP (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: July 11, 2023
    Assignees: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Satoshi Takagi, Yumiko Kagawa, Yasuhiko Suzuki, Chie Nakajima
  • Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
    Patent number: 11690899
    Abstract: The present invention relates to the field of medicine, specifically the field of bacterial infection and treatment thereof.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: July 4, 2023
    Assignee: Micreos Human Health B.V.
    Inventor: Fritz Eichenseher
  • Tetanus toxoid and CCL3 improve DC vaccines
    Patent number: 11684662
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Grant
    Filed: July 11, 2021
    Date of Patent: June 27, 2023
    Assignee: Duke University
    Inventors: John H Sampson, Duane A Mitchell, Kristen A Batich, Michael D Gunn
  • Peptides and antibodies for the removal of biofilms
    Patent number: 11684673
    Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: June 27, 2023
    Assignee: Research Institute at Nationwide Children's Hospital
    Inventors: Lauren O. Bakaletz, Steven D. Goodman